"There is a dedicated investor sector in Biotechs, which ANP was always been part of, so it was able to get that general liquidity from the sector trading it as part of a portfolio. PNO has never made that pool. Not enough IP around it's so called wonder pain drug tripeptofen. This is the missing link, why have they spent no money on proving up tripeptofen!!!? now PNO needs a partner and partners don't usually get involved until phase 2 and even three have been completed!, we havn't even thought about phase 1 yet!!.."
Hi Motors,
Existing product approvals in Australia + 18 year clinical safety and efficacy record = Ability to move directly to Phase III clinical trials for new indications + Ability to move directly into IND and EMEA compliant regulatory programs
Imo, ANP are a bit of a traders play thing - They've been singing exactly the same song for over 10 years now, and at that rate, their patents will expire long before they get anything to market. Imo, they also spend far too much time promoting other companies developments, like Elan's failed antisense tech back in 2003, and judging by their current promotion of Mipomersen when looking at this Independent Expert survey, it would appear they still haven't learnt a lesson.
PNO - 2009 - Boxes are being ticked... The Company has remained in contact with potential Pharma partners and the collaborator networks it had generated in previous periods. International marketing activities have not been a priority for the current period. Once production and sales are established in Australia, and further international patents granted, the Company anticipates that its international business development activities will become a greater focus. The Group’s technology platform is derived from a product with an unblemished safety and efficacy record for more than 18 years. Safety and efficacy are the two most critical aspects in mediating risks in new drug discoveries
When comparing Tripeptofen with the market leader, global sales for diclofenac exceeds US$1 billion per year, despite its slow action, limited biological activity and serious safety concerns...
Tripeptophen Prostaglandins v Cox-1, Cox-2 v TNF-a v TACE v Bradykinin v Apoptosis v Onset of action: fast
Voltaren Emulgel (Diclofenac) Prostaglandins v Cox-1, Cox-2 v TNF-a X TACE X Bradykinin X Apoptosis X Onset of action: slow
TNF-a - Tumor Necrosis Factor alpha is one of the most commercially significant targets in the management of inflammation and inflammatory disease. The scientific data, provided by internationally respected research organisations, have shown that the drug development platform of the Group inhibits the binding of TNF-a at very low concentrations, which makes it an ideal candidate for products and new molecular entities targeted at rheumatoid arthritis, lupus, inflammatory bowel disease, and inflammatory skin diseases.
TACEis a converting enzyme necessary for the release of pro inflammatory components. The ability to inhibit TACE at concentrations as low as 1.3% makes the specific development candidate a potentially important new topically deliverable mediator for inflammatory and post-injury processes in both the therapeutic and cosmetic applications.
Bradykininsare proinflammatory peptides involved in numerous vascular and pain responses following injury. It is this activity when combined with other non-diclosed activities, that is believed to provide much of the fast acting analgesic properties. Commercial applications include local neurological and pain responses, blunt trauma, neurological deficit and in inflammationinduced secondary damage.
In 2007 Pharmanet was invited by the Scientific Programme Committee of the 8th World Congress on Inflammation to presentthreeseparate scientific papers on its advanced topical anti-cytokine and anti-inflammatory drug developments. The World Congress on Inflammation is the premier scientific forum for new discoveries in inflammation control and management. To havethreepapers accepted at such a prestigious forum provides a strong endorsement of the scientific quality of PNO’s drug discovery program.
Being invited to present three papers at this forum was a strong endorsement, so why would they omit advising the market about the fourth...?
P12.09 A NOVEL TOPICAL ANTI-CYTOKINE EFFECTIVE IN SUN BURN RECOVERY Maud Eijkenboom, P Hart, J Edwards, C Quirk
P12.10 ZN-PLASMA PROTEIN COMPLEX REDUCES CYTOKINES IN LPS-STIMULATED MONOCYTES A Downs, P Hart, J Snowden, Maud Eijkenboom
P07.12 INFLUENCE OF TRACE ELEMENTS ON THE TNF-ALPHA SUPPRESSION OF AN ARTHRITIC CREAM Heather Benson, P Hart, A Barker, M Eijkenboom
P01.09 DERMAPORTATION TREATED SKIN IS MORE PERMEABLE TO VOLTAREN EMULGEL Heather Benson, R Caccetta, M Eijkenboom, J Edwards
(20min delay)